Freeline touts positive data for Gaucher disease therapy
The positive Phase I/II data has supported a RMAT designation from the FDA and a PRIME designation by the EMA.
The positive Phase I/II data has supported a RMAT designation from the FDA and a PRIME designation by the EMA.
What's Your Reaction?
